PONTE VEDRA BEACH, Fla., July 29, 2021– RedDress, a privately held U.S. and Israel-based wound care company, today announced that it will sponsor an episode on the Virtual Wound Rounds Webinar. The episode will focus on “The Diabetic Foot” and will be held on July 29th from 5:30pm – 7:00pm EST.

 

Virtual Wound Rounds was developed by Frank Aviles Jr., PT, CWS, FACCWS, CLT, ALM, AWCC during the COVID-19 pandemic. Aviles created Virtual Wound Round as an educational series for students to complete their wound clinical rotations and learn about wound care. The webinar series proved to be successful and has been continued into 2021.

 

Each episode focuses on a different wound complication and features wound specialists speaking to how they would address and care for the ailment. The session held on July 29th will focus on “The Diabetic Foot” and will feature a conversation between Dr. Robert Snyder, DPM, MSc, MBA, CWSP; Eric Lullove, DPM, PA and Pamela Cole, MSPT, CWS. Dr. Robert Snyder, Professor and Director of Clinical Research at Barry University School of Podiatric Medicine, will highlight the technology behind ActiGraft® system – an FDA-cleared wound solution for chronic wounds – and how it can be used to help heal diabetic foot ulcers.

 

“It is estimated that around 20% of diabetics will develop a diabetic foot ulcer. At RedDress, we are committed to advancing the treatment of chronic wounds which includes increasing awareness and promoting education,” says Alon Kushnir, CEO of RedDress. “By partnering with Virtual Wound Rounds and Frank Aviles Jr., we are able to facilitate a conversation around diabetic foot ulcers and its complications.”

 

To register for the webinar, visit: https://virtualwoundrounds.com/.

 

 

About ActiGraft

 

ActiGraft based on RedDress’ proprietary patented technology, is an FDA-cleared wound care solution that enables health care providers to produce – in real time – an in vitro blood clot from a patient’s whole blood. Once applied, the blood clot serves as a protective covering and supports wound healing processes which naturally occur in the patient’s body.

 

ActiGraft is intended for exuding cutaneous wounds. ActiGraft includes blood-contacting components that have been sterilized by Ethylene Oxide, which may cause serious allergic reactions in patients that are sensitized. For full prescribing information, visit www.reddressmedical.com/safety-info.

 

 

About RedDress

RedDress (www.reddressmedical.com) is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural, and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.

 

 

Press & Media Inquiries

Alessandra Lalli, RedDress

alalli@reddressmedical.com

 

Investor Inquiries

Russell Lalli, RedDress

rlalli@reddressmedical.com

 

###

ActiGraft® is a registered trademark of RedDress Ltd.

 

crossmenu